{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:26Z","timestamp":1790717006225,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":3490,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.jacc.2003.09.043","type":"journal-article","created":{"date-parts":[[2004,2,14]],"date-time":"2004-02-14T10:22:28Z","timestamp":1076754148000},"page":"519-525","source":"Crossref","is-referenced-by-count":90,"title":["Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk"],"prefix":"10.1016","volume":"43","author":[{"given":"Patricia A","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Delafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2003.09.043_BIB1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/heart.85.3.265","article-title":"Aspirin for primary prevention of coronary heart disease","volume":"85","author":"Sanmuganathan","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2003.09.043_BIB2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-136-2-200201150-00015","article-title":"Aspirin for the primary prevention of cardiovascular events","volume":"136","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB3","first-page":"81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy-I","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2003.09.043_BIB4","doi-asserted-by":"crossref","unstructured":"Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC\/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34;890\u2013911.","DOI":"10.1016\/S0735-1097(99)00351-4"},{"key":"10.1016\/j.jacc.2003.09.043_BIB5","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJM199106133242407","article-title":"Nonsteroidal anti-inflammatory drugs\u2014differences and similarities","volume":"324","author":"Brooks","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2003.09.043_BIB7","unstructured":"IMS reports 16.9% growth in 2001 U.S. prescription sales. Westport, CT: IMS Health Inc., April 26, 2002. Available at: http:\/\/www.imshealth.com\/public\/structure\/dispcontent\/1,2779,1203- 1203-144055,00.html. Accessibility verified December 16, 2002."},{"key":"10.1016\/j.jacc.2003.09.043_BIB8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"issue":"3A","key":"10.1016\/j.jacc.2003.09.043_BIB9","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","article-title":"Mechanism of action of nonsteroidal anti-inflammatory drugs","volume":"104 Suppl","author":"Vane","year":"1998","journal-title":"Am J Med"},{"issue":"Suppl 25","key":"10.1016\/j.jacc.2003.09.043_BIB10","first-page":"S41","article-title":"The effect of NSAIDs on the risk of coronary heart disease","volume":"19","author":"Rodriguez","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs","volume":"104","author":"Cryer","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/284271a0","article-title":"Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa","volume":"284","author":"Whittle","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2003.09.043_BIB13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2003.09.043_BIB15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2003.09.043_BIB16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"Fitzgerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2003.09.043_BIB19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2003.09.043_BIB20","first-page":"1623","article-title":"A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"29","author":"Matsumoto","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0002-9149(01)02201-9","article-title":"Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal antiinflamamtory drugs (ibuprofen, diclofenac, and nabumetone)","volume":"89","author":"Reicin","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2003.09.043_BIB23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","article-title":"Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor versus ibuprofen or diclofenac","volume":"89","author":"White","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archinte.163.4.481","article-title":"Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly","volume":"163","author":"Mamdani","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.162.10.1099","article-title":"Nonsteroidal anti-inflammatory drug use and acute myocardial infarction","volume":"162","author":"Solomon","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.162.10.1105","article-title":"Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis","volume":"162","author":"Watson","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archinte.162.10.1111","article-title":"Association between naproxen use and protection against acute myocardial infarction","volume":"162","author":"Rahme","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","article-title":"Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"359","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2003.09.043_BIB29","doi-asserted-by":"crossref","unstructured":"Ko D, Wang Y, Berger AK, et al. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J 2002;143:475\u201381.","DOI":"10.1067\/mhj.2002.121270"},{"issue":"Suppl 25","key":"10.1016\/j.jacc.2003.09.043_BIB30","first-page":"S31","article-title":"COX-2 inhibitors and the cardiovascular system","volume":"19","author":"Fitzgerald","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB31","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.93.19.10417","article-title":"Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli","volume":"93","author":"Topper","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jacc.2003.09.043_BIB32","doi-asserted-by":"crossref","first-page":"10197","DOI":"10.1073\/pnas.97.18.10197","article-title":"Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits","volume":"97","author":"Shinmura","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jacc.2003.09.043_BIB33","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0008-6363(02)00414-5","article-title":"Discovery of a new function of cyclooxygenase (COX)-2","volume":"55","author":"Bolli","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2003.09.043_BIB34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/hc3301.092790","article-title":"Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries","volume":"104","author":"Hennan","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2003.09.043_BIB35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI200111334","article-title":"Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo","volume":"108","author":"Dowd","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2003.09.043_BIB36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"issue":"Suppl","key":"10.1016\/j.jacc.2003.09.043_BIB37","doi-asserted-by":"crossref","first-page":"33D","DOI":"10.1016\/S0002-9149(02)02235-X","article-title":"Relative risk of cardiovascular events in patients with rheumatoid arthritis","volume":"89","author":"DeMaria","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3949\/ccjm.68.11.961","article-title":"The data are inconclusive and these drugs are needed","volume":"68","author":"Lipani","year":"2001","journal-title":"Cleve Clin J Med"},{"issue":"Suppl 25","key":"10.1016\/j.jacc.2003.09.043_BIB39","first-page":"S77","article-title":"Controversies in COX-2 inhibitor therapy","volume":"19","author":"Abramson","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","article-title":"Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers","volume":"40","author":"VanHecken","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2003.09.043_BIB41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archinte.162.10.1091","article-title":"Selective COX-2 inhibitors, NSAIDs, aspirin and myocardial infarction","volume":"162","author":"Dalen","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2003.09.043_BIB42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/01.CIR.0000051361.69808.3A","article-title":"Selective COX-2 inhibition improves endothelial function in coronary artery disease","volume":"107","author":"Chenevard","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2003.09.043_BIB43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.CIR.0000021599.56755.A1","article-title":"Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation","volume":"106","author":"Altman","year":"2002","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109703015547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109703015547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T23:55:36Z","timestamp":1682639736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109703015547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0735109703015547"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2003.09.043","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}